Steven Yatomi-Clarke – CEO and Managing Director
Prior to being appointed CEO and Managing Director, Steven Yatomi-Clarke was a Non-Executive Director of Prescient Therapeutics.
Mr Yatomi-Clarke has a distinguished career in Australian capital markets with a particular focus on the life sciences sector, where he previously held a position as a Director in Corporate Finance at Patersons Securities. During this time, he played a leading role as both a corporate advisor and fund raiser to many biotechnology companies and was consistently one of the country’s most prolific and successful healthcare bankers.
Mr Yatomi Clarke has also been a long-standing collaborator on immuno-oncology clinical studies in US and Australia.
Paul Hopper, Executive Director
Paul Hopper has more than 20 years’ experience in international public company markets, with a focus on start-up and rapid growth companies where he has served as either Chairman, Non-Executive Director or CEO. His focus has been primarily in the life-sciences sector, steering around fourteen public companies in the US, Australia, and Asia.
Terrence Chew, Chief Medical Officer
Terrence Chew, M.D., R.A.C. has over 30 years of experience in pharmaceutical drug development, clinical trials and regulatory approval worldwide for both small biotech and large pharmaceutical companies. He has been involved in the development and approval of several anti-cancer drugs, including Taxotere, Daunoxome, DepoCyt and Ibrance. He received his MD degree from the University of California, Los Angeles.
Professor Said M. Sebti, Ph.D., Chief Scientific Officer
Professor Said Sebti is highly regarded as a pioneer of global cancer research. After spending more than two decades of dedicated laboratory investigations and molecular-level research, Dr Sebti’s work has resulted in over 35 issued patents, 280 research articles, the training and mentoring of dozens of scientists and graduate students, and – with his team at Florida’s Moffitt Cancer Center and other collaborators– the discovery of seven licensed drugs that hold hope for thousands of cancer sufferers.